Earnings calls

J B Chemicals & concall ledger

Every earnings call for JBCHEPHARM — management tone, guidance, KPIs and promise tracking, quarter by quarter.

JBCHEPHARM · 6 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 12 May 2026Call held 12 May 2026

JBCHEPHARM Q4 FY26 Earnings Call Transcript & Analysis

Revenue₹904 cr−5% YoYAdjusted EBITDA₹241 crAdjusted EBITDA Margin27%Reported PAT₹101 crGross Margin70%

Revenue ₹904 cr (−5% YoY); Adjusted EBITDA ₹241 cr; Adjusted EBITDA Margin 27%. Revenue of INR 904 crores, registering a de-growth of 5% YoY due to operational reset.

Read full transcript & analysis

Q2 FY26Published 19 Jan 2026Call held 19 Jan 2026

JBCHEPHARM Q2 FY26 Earnings Call Transcript & Analysis

Revenue₹1,065 cr+11% YoYOperating EBITDA₹305 cr+13% YoYEBITDA Margin28.7%PAT₹198 cr+22% YoYGross Margin69.1%

Revenue ₹1,065 cr (+11% YoY); Operating EBITDA ₹305 cr (+13% YoY); EBITDA Margin 28.7%. Revenue grew 11% YoY to ₹1,065 crore, driven by domestic chronic portfolio and international formulations.

Read full transcript & analysis

Q1 FY26Published 31 Jul 2025Call held 31 Jul 2025

JBCHEPHARM Q1 FY26 Earnings Call Transcript & Analysis

Revenue₹1,094 cr+9% YoYOperating EBITDA₹330 cr+13% YoYEBITDA Margin30.2%PAT₹214 cr+21% YoYGross Margin68.3%

Revenue ₹1,094 cr (+9% YoY); Operating EBITDA (Adj) ₹330 cr (+13% YoY); EBITDA Margin (Adj) 30.2%. Revenue reached ₹1,094 crore, representing a 9% year-on-year growth.

Read full transcript & analysis

Q4 FY25Published 15 May 2025Call held 15 May 2025

JBCHEPHARM Q4 FY25 Earnings Call Transcript & Analysis

Revenue₹949 cr+10% YoYOperating EBITDA₹240 cr+15% YoYEBITDA Margin25.3%Net Profit₹146 cr+15% YoYGross Margin66.1%

Revenue ₹949 cr (+10% YoY); Operating EBITDA ₹240 cr (+15% YoY); EBITDA Margin 25.3%. Revenue for Q4 FY25 grew 10% YoY to ₹949 crore; full-year FY25 revenue reached ₹3,918 crore (up 12%).

Read full transcript & analysis

Q3 FY25Published 05 Feb 2025Call held 05 Feb 2025

JBCHEPHARM Q3 FY25 Earnings Call Transcript & Analysis

Revenue₹963 cr+14% YoYOperating EBITDA₹270 cr+15% YoYEBITDA Margin28.1%Net Profit₹162 cr+22% YoYGross Margin67.1%

Revenue ₹963 cr (+14% YoY); Operating EBITDA ₹270 cr (+15% YoY); EBITDA Margin 28.1%. Revenue grew 14% YoY to ₹963 crores, maintained quarterly run rate.

Read full transcript & analysis

Q2 FY25Published 07 Nov 2024Call held 07 Nov 2024

JBCHEPHARM Q2 FY25 Earnings Call Transcript & Analysis

Revenue₹1,001 cr+13% YoYOperating EBITDA Margin28.4%Net Profit₹175 cr+16% YoYGross Margin66.2%

Revenue ₹1,001 cr (+13% YoY); Operating EBITDA Margin 28.4%; Net Profit ₹175 cr (+16% YoY). Revenue reached ₹1,001 crore for the quarter, representing a 13% YoY increase.

Read full transcript & analysis